Lantern Pharma Inc. LTRN Archives

MondayAug 25, 2025 1:15 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2 studies in cancers with large market potential. Early patient responses across LP-184, LP-284, and LP-300 trials highlight clinical activity in difficult-to-treat cancers. Intellectual property expanded with new European patent allowance for LP-284 and publication of blood-brain barrier prediction patent. Enhancements to RADR(R), the company’s AI platform, include public launch of predictBBB.ai(TM) and a new drug combination module. Lantern ended Q2 with $15.9 million in cash and expects its runway to extend into mid-2026. R&D expenses declined year-over-year, reflecting disciplined cost control while advancing multiple trials.…

TuesdayAug 19, 2025 10:30 am

Lantern Pharma Inc. (NASDAQ: LTRN) Releases Latest AI Breakthrough for Central Nervous System (‘CNS’) Drug Development with predictBBB.ai (TM): A High-Accuracy Open-Access AI Drug Development Tool

Lantern Pharma has publicly launched predictBBB.ai (TM), its AI-driven module for predicting small-molecule blood-brain barrier permeability. The tool achieves 94% prediction accuracy, with 95% sensitivity and 89% specificity, based on real-time ensemble machine learning. Powered by Lantern’s vast molecular features data lake and ensemble algorithms, the platform sets a new computational benchmark for CNS drug discovery. Lantern hosts additional predictive and analytical modules in development, leveraging its large-scale data infrastructure and algorithmic approach. The tool is publicly accessible through a freemium model, aiming to drive adoption, strategic partnerships, and accelerate CNS therapeutic development. Lantern Pharma subsidiary Starlight Therapeutics secures FDA…

ThursdayAug 07, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule

The trial targets never-smoker non-small cell lung cancer (“NSCLC”) patients, a group with limited treatment options. Japan’s high incidence of never-smoker NSCLC makes it a strategic region for the trial. LP-300 is being tested alongside standard chemotherapy agents in patients who have relapsed after tyrosine kinase inhibitor therapy. Lantern's AI-driven approach may help identify and accelerate development of therapies in underserved cancer markets. Additional trial data from Taiwan and the U.S. is expected later in Q3 2025. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development, has completed targeted patient…

WednesdayAug 06, 2025 12:10 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations

Lantern Pharma has introduced an AI-powered module within its RADR(R) platform to assess DDA-DDRi combination therapies. The module uses genomic, transcriptomic, and clinical data, to predict treatment synergy and patient response, and supported the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer. A review of 221 clinical trials informed the development of the predictive algorithm. Non-PARP DDRi combinations with DNA-damaging agents showed strong outcomes in specific cancer subtypes. Lantern is evaluating licensing opportunities to commercialize the module for broader oncology use. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine…

MondayAug 04, 2025 9:30 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug development company, has launched predictBBB.ai(TM), a public AI module that predicts blood-brain barrier (BBB) permeability of small molecules with 94% accuracy, 95% sensitivity, and 89% specificity. Built on billions of molecular data points from Lantern’s proprietary data lake, the platform addresses the pharmaceutical challenge that only 2–6% of small molecules can cross the BBB. PredictBBB.ai(TM) ranks among the top performers on the Therapeutic Data Commons Leaderboard, leveraging synthetic data augmentation and advanced molecular representation to process compounds in real time. The launch comes as the BBB technologies market is projected to grow…

MondayJul 28, 2025 9:00 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence and genomic data to accelerate oncology drug discovery, announced the appointment of Lee T. Schalop, MD, to its Board of Directors. Dr. Schalop, co-founder and former CEO of Oncoceutics Inc., brings over 20 years of experience in biotechnology leadership and financial markets, with a track record in developing targeted therapies for solid tumors, including HK327M-mutant gliomas. Oncoceutics was acquired by Chimerix Inc. (NASDAQ: CMRX) for $450 million in 2021 and later by Jazz Pharmaceuticals for $935 million in April 2025. Lantern CEO Panna Sharma said Dr. Schalop’s expertise in…

MondayJul 21, 2025 9:40 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284

Lantern Pharma (NASDAQ: LTRN) announced the European Patent Office has issued a notice of allowance for a composition of matter patent covering LP-284, a clinical-stage drug candidate for relapsed or refractory non-Hodgkin's lymphoma. The patent, expected to grant with exclusivity through 2039, adds to existing IP in the U.S. and Japan and supports global commercialization efforts. LP-284, developed using Lantern’s RADR(R) AI platform, is in Phase 1 trials and holds Orphan Drug Designations for MCL and HGBL. The drug targets a $4 billion global market, and its rapid development timeline and cost efficiency bolster Lantern’s strategic partnership potential. To view…

TuesdayJul 15, 2025 11:20 am

QualityStocksNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology drug developer, announced the launch of a new AI-powered module within its RADR(R) platform to predict the efficacy of combination therapies involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis). Backed by a peer-reviewed analysis of 221 clinical trials, the tool enables precise, biomarker-guided design of cancer treatment regimens, reducing development time and cost by up to one-third. The platform guided the design of Lantern’s FDA-cleared Phase 1B/2 trial in triple-negative breast cancer combining LP-184 and olaparib. Lantern is exploring licensing and commercialization opportunities to scale the system across oncology indications. To…

MondayJun 30, 2025 1:12 pm

QualityStocksNewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company, is leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. “Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline,” reads a recent article. “The company has three lead drug candidates in clinical development, targeting major oncology markets including non-small cell lung cancer (‘NSCLC’), triple-negative breast cancer (‘TNBC’), and non-Hodgkin’s lymphoma (‘NHL’)… Starlight Therapeutics extends Lantern’s footprint into…

ThursdayJun 26, 2025 9:45 am

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial

Lantern Pharma uses a proprietary AI platform, RADR®, to guide its oncology drug development, enabling rapid drug candidate identification and targeted trial design based on genomic and biomarker data. A Phase 2 trial patient achieved a complete response in their primary cancer lesions after multiple prior therapies failed and has remained responsive to LP-300 for two years signaling durable clinical benefit in this challenging population. The target population, never-smokers with non-small cell lung cancer, represents a growing global unmet need estimated at over $4 billion annually. Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotechnology company leveraging artificial intelligence and machine learning…

Site Search

Company Search

Tag: Lantern Pharma Inc. LTRN